MCID: MNN032
MIFTS: 45

Meningococcal Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Meningitis

MalaCards integrated aliases for Meningococcal Meningitis:

Name: Meningococcal Meningitis 12 60 15 17 74
Meningitis, Meningococcal 77 45
Meningitis Meningococcal 56

Characteristics:

Orphanet epidemiological data:

60
meningococcal meningitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (New Zealand),1-9/1000000 (United States);

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0080176
ICD9CM 36 036.0
MeSH 45 D008585
ICD10 34 A39.0
MESH via Orphanet 46 D008585
ICD10 via Orphanet 35 A39.0+ G01*
UMLS via Orphanet 75 C0025294
Orphanet 60 ORPHA33475
UMLS 74 C0025294

Summaries for Meningococcal Meningitis

Disease Ontology : 12 A bacterial meningitis that has material basis in Neisseria meningitidis infection.

MalaCards based summary : Meningococcal Meningitis, also known as meningitis, meningococcal, is related to meningitis and meningococcemia. An important gene associated with Meningococcal Meningitis is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Creation of C4 and C2 activators. The drugs Ciprofloxacin and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and b cells.

Wikipedia : 77 Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis (also termed... more...

Related Diseases for Meningococcal Meningitis

Diseases related to Meningococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 meningitis 31.6 C6 CFP MBL2 TLR9
2 meningococcemia 30.8 CFP MBL2
3 membranoproliferative glomerulonephritis 30.3 CFH CFP
4 glomerulonephritis 30.2 CFH CFP TLR9
5 neisseria meningitidis infection 30.1 CFP MBL2
6 complement deficiency 29.7 C7 CFH CFP MBL2
7 pericarditis 10.3
8 adult dermatomyositis 10.2 MBL2 TLR9
9 endophthalmitis 10.2
10 scabies 10.2 CFP MBL2
11 mannose-binding lectin deficiency 10.2 CFP MBL2
12 streptococcal meningitis 10.2 CFP MBL2
13 invasive aspergillosis 10.2 MBL2 TLR9
14 3mc syndrome 10.2 CFP MBL2
15 aspergillosis 10.2 MBL2 TLR9
16 arthritis 10.2
17 waterhouse-friderichsen syndrome 10.2
18 bacterial meningitis 10.1 CFP TLR9
19 immunodeficiency due to a late component of complement deficiency 10.1 C6 C7
20 immune deficiency disease 10.1 CFH TLR9
21 cardiac tamponade 10.1
22 paraplegia 10.1
23 bacterial infectious disease 10.1 CFP MBL2 TLR9
24 iga glomerulonephritis 10.0 CFP MBL2
25 complement component 7 deficiency 10.0
26 malaria 10.0
27 rigidity and multifocal seizure syndrome, lethal neonatal 10.0
28 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
29 thrombosis 10.0
30 subdural empyema 10.0
31 hemopericardium 10.0
32 pericardial effusion 10.0
33 panophthalmitis 10.0
34 facial paralysis 10.0
35 pleural empyema 10.0
36 vasculitis 10.0
37 haemophilus influenzae 10.0
38 spinal cord infarction 10.0
39 hemolytic uremic syndrome, atypical 1 10.0 CFH CFP
40 opportunistic mycosis 9.9 ST5 TLR9
41 pulmonary tuberculosis 9.9 MBL2 TLR9
42 systemic lupus erythematosus 9.9
43 chiari malformation type ii 9.9
44 atrioventricular dissociation 9.9
45 hypoascorbemia 9.9
46 stroke, ischemic 9.9
47 aceruloplasminemia 9.9
48 complement component 5 deficiency 9.9
49 complement component 6 deficiency 9.9
50 complement component 8 deficiency, type ii 9.9

Graphical network of the top 20 diseases related to Meningococcal Meningitis:



Diseases related to Meningococcal Meningitis

Symptoms & Phenotypes for Meningococcal Meningitis

Drugs & Therapeutics for Meningococcal Meningitis

Drugs for Meningococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4,Not Applicable 85721-33-1 2764
2 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
3 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Cytochrome P-450 Enzyme Inhibitors Phase 4
7 Anti-Infective Agents Phase 4
8 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
9 Anti-Bacterial Agents Phase 4,Not Applicable
10 Topoisomerase Inhibitors Phase 4
11 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
12
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 15589840 11953898
13
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
14
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
15
Lactitol Investigational Phase 3,Phase 2 585-88-6, 585-86-4 493591
16
Cobalamin Experimental Phase 2, Phase 3,Phase 3 13408-78-1 6857388
17 Vitamin B12 Phase 2, Phase 3,Phase 3
18 Vitamin B 12 Phase 2, Phase 3,Phase 3
19 Laxatives Phase 3,Phase 2
20 Cathartics Phase 3,Phase 2
21 Gastrointestinal Agents Phase 3,Phase 2
22 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
23 Antacids Phase 2, Phase 3
24 Anti-Ulcer Agents Phase 2, Phase 3
25 Adjuvants, Immunologic Phase 2, Phase 3
26
Aluminum sulfate Approved Phase 2 10043-01-3
27 Antipyretics Phase 2
28 Antibiotics, Antitubercular Not Applicable

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
2 Ciprofloxacin for the Prevention of Meningococcal Meningitis Completed NCT02724046 Phase 4 Ciprofloxacin
3 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
4 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
5 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
6 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
7 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
8 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
9 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
10 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
11 A Sourcing Study to Collect Human Blood Samples From Healthy Adults Recruiting NCT03493919 Phase 4
12 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population Recruiting NCT03682939 Phase 4
13 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
14 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Not yet recruiting NCT03431675 Phase 4 Ciprofloxacin
15 Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed NCT01423084 Phase 3
16 Comparison of Two Meningococcal ACWY Conjugate Vaccines Completed NCT01192997 Phase 2, Phase 3
17 Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine Completed NCT01148017 Phase 3
18 Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Completed NCT03077438 Phase 3
19 Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine Completed NCT00856297 Phase 3
20 Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers Completed NCT00667602 Phase 3
21 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 Completed NCT00944034 Phase 2, Phase 3
22 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Completed NCT02955797 Phase 3
23 Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00657709 Phase 3
24 Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 Completed NCT01894919 Phase 3
25 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
26 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed NCT01478347 Phase 3
27 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults Completed NCT00474487 Phase 3
28 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed NCT01339923 Phase 3
29 A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Completed NCT01274897 Phase 3
30 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life Completed NCT01214837 Phase 3
31 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed NCT01148524 Phase 2, Phase 3
32 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults Completed NCT00450437 Phase 3
33 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years Completed NCT00329901 Phase 3
34 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older Completed NCT02842866 Phase 3
35 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed NCT02842853 Phase 3
36 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed NCT02752906 Phase 3
37 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed NCT01519713 Phase 3
38 Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Completed NCT03714737 Phase 3
39 Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children Completed NCT03476135 Phase 3
40 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
41 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
42 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed NCT00384397 Phase 3
43 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Completed NCT00518180 Phase 3
44 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed NCT01453348 Phase 3
45 Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants Completed NCT00161928 Phase 3
46 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
47 Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age Completed NCT00310674 Phase 3
48 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Completed NCT00474526 Phase 3
49 Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children Completed NCT00311415 Phase 3
50 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults Completed NCT01755689 Phase 3

Search NIH Clinical Center for Meningococcal Meningitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: meningitis, meningococcal

Genetic Tests for Meningococcal Meningitis

Anatomical Context for Meningococcal Meningitis

MalaCards organs/tissues related to Meningococcal Meningitis:

42
Testes, Spinal Cord, B Cells, Skin, Brain, Colon, Bone

Publications for Meningococcal Meningitis

Articles related to Meningococcal Meningitis:

(show top 50) (show all 534)
# Title Authors Year
1
Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review. ( 30937163 )
2019
2
A case of a FilmArray ME false negative in meningococcal meningitisA case of a FilmArray® ME false negative in meningococcal meningitis. ( 31102602 )
2019
3
Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis. ( 30856166 )
2019
4
Meningococcal Meningitis. ( 30860561 )
2019
5
Fatal meningococcal meningitis in a 2-year-old child: A case report. ( 30863763 )
2019
6
Subdural effusion and ischemic stroke complicating meningococcal meningitis in an adult. ( 30497911 )
2019
7
Meningococcal meningitis presenting postinfant group B meningococcal immunisation. ( 30518518 )
2018
8
Epidemics of meningococcal meningitis in Northern Nigeria focus on preventive measures. ( 30588927 )
2018
9
Rare vascular complication of acute meningococcal meningitis in a child. ( 30373900 )
2018
10
Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis. ( 29923041 )
2018
11
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial. ( 29944651 )
2018
12
Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis. ( 30089105 )
2018
13
Meningococcal Meningitis Complicated by Ventriculitis in an Infant. ( 29417667 )
2018
14
Cerebral Venous Sinus Thrombosis in a Patient with Meningococcal Meningitis. ( 29468001 )
2018
15
A refugee patient with meningococcal meningitis type B. ( 29757696 )
2018
16
Reply to "A refugee patient with meningococcal meningitis type B." ( 29792550 )
2018
17
Meningococcal meningitis with neurological complications and meningococcemia due to serogroup W sequence type 11 complex. ( 29373268 )
2018
18
Uncommon mixed outbreak of pneumococcal and meningococcal meningitis in Jirapa District, Upper West Region, Ghana, 2016. ( 29622828 )
2017
19
Effects of meteorological factors on the incidence of meningococcal meningitis. ( 29085410 )
2017
20
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial. ( 28646924 )
2017
21
Deep coal mining and meningococcal meningitis in England and Wales, 1931-38: Ecological study, with implications for deep shaft mining activities worldwide. ( 28813690 )
2017
22
An atypical form of infantile meningococcal meningitis. ( 28389430 )
2017
23
Bilateral abducens nerve palsy as the initial clinical manifestation of meningococcal meningitis. ( 27876190 )
2017
24
Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. ( 28081671 )
2017
25
Reversible splenial lesion of the corpus callosum associated with meningococcal meningitis. ( 28131233 )
2017
26
The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease. ( 27604766 )
2016
27
Detection of meningococcal meningitis in cerebrospinal fluid of patients with neurological disorders in government hospitals of Karachi. ( 27812059 )
2016
28
Meningococcal meningitis: clinical and laboratorial characteristics, fatality rate and variables associated with in-hospital mortality. ( 27901251 )
2016
29
Invasive Meningococcal Meningitis Serogroup C Outbreak in Northwest Nigeria, 2015 - Third Consecutive Outbreak of a New Strain. ( 27508101 )
2016
30
Callosal disconnection syndrome after ischemic stroke of the corpus callosum due to meningococcal meningitis: A case report. ( 27653875 )
2016
31
Serogroup-Specific Characteristics of Localized Meningococcal Meningitis Epidemics in Niger 2002-2012 and 2015: Analysis of Health Center Level Surveillance Data. ( 27657530 )
2016
32
Atypical clinical presentation of meningococcal meningitis: a case report. ( 27668905 )
2016
33
Neonatal Meningococcal Meningitis In France From 2001 To 2013. ( 27753774 )
2016
34
Notes from the Field: Expanded Chemoprophylaxis Offered in Response to a Case of Meningococcal Meningitis in an Elementary School - Indiana, 2015. ( 27227736 )
2016
35
Pattern of the meningococcal meningitis outbreak in Northern Nigeria, 2009. ( 26724773 )
2016
36
A case of meningococcal meningitis that was difficult to treat owing to concurrent ventriculitis. ( 27151225 )
2016
37
Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitidis serogroup C in Africa: recommendations from a WHO expert consultation. ( 26591025 )
2015
38
Climate Regimes, El Niño-Southern Oscillation, and Meningococcal Meningitis Epidemics. ( 26284234 )
2015
39
A case of meningococcal meningitis with multiple cerebellar microbleeds detected by susceptibility-weighted imaging. ( 26489936 )
2015
40
Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013. ( 26553668 )
2015
41
Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt. ( 25878213 )
2015
42
Prevalence of meningococcal meningitis in China from 2005 to 2010. ( 25444796 )
2015
43
Incidence, carriage and case-carrier ratios for meningococcal meningitis in the African meningitis belt: a systematic review and meta-analysis. ( 25658307 )
2015
44
Meningococcal meningitis with meningococcemia: a rare sporadic case in an elderly patient with no history of contact with infected individuals. ( 25420647 )
2015
45
An Adolescent Boy Presenting with Complicated Meningococcal Meningitis Serogroup A: What Is the State of Community Awareness for This Serious Disease? ( 26175987 )
2014
46
A Syrian patient diagnosed with meningococcal meningitis serogroup B. ( 25424959 )
2014
47
Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. ( 25551808 )
2014
48
Epidemiological characteristics of meningococcal meningitis in the area of zenica-doboj canton in period from 2008 to 2012. ( 25568534 )
2014
49
Meningococcal meningitis C in Tamil Nadu, public health perspectives. ( 25657960 )
2014
50
Epidemiological characteristics of meningococcal meningitis in the area of Zenica-Doboj Canton in period from 2008 to 2012. ( 25195353 )
2014

Variations for Meningococcal Meningitis

Expression for Meningococcal Meningitis

Search GEO for disease gene expression data for Meningococcal Meningitis.

Pathways for Meningococcal Meningitis

GO Terms for Meningococcal Meningitis

Cellular components related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 C6 C7 CFH CFP MBL2 TLR9
2 membrane attack complex GO:0005579 8.62 C6 C7

Biological processes related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.71 C6 C7 CFP TLR9
2 defense response to bacterium GO:0042742 9.61 CFP MBL2 TLR9
3 regulation of complement activation GO:0030449 9.56 C6 C7 CFH CFP
4 complement activation, classical pathway GO:0006958 9.54 C6 C7 MBL2
5 innate immune response GO:0045087 9.43 C6 C7 CFH CFP MBL2 TLR9
6 complement activation, alternative pathway GO:0006957 9.33 C7 CFH CFP
7 cytolysis GO:0019835 9.32 C6 C7
8 complement activation GO:0006956 9.02 C6 C7 CFH CFP MBL2

Molecular functions related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 8.32 TPSB2

Sources for Meningococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....